These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22826562)

  • 1. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
    Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
    Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.
    Okamoto A; Yanada M; Miura H; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
    Cancer Sci; 2015 Nov; 106(11):1576-81. PubMed ID: 26353084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.
    Suzuki R; Yamaguchi M; Izutsu K; Yamamoto G; Takada K; Harabuchi Y; Isobe Y; Gomyo H; Koike T; Okamoto M; Hyo R; Suzumiya J; Nakamura S; Kawa K; Oshimi K;
    Blood; 2011 Dec; 118(23):6018-22. PubMed ID: 21984805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.
    Kim HS; Kim KH; Kim KH; Chang MH; Ji SH; Lim DH; Kim K; Kim SJ; Ko Y; Ki CS; Jo SJ; Lee JW; Kim WS
    Leuk Lymphoma; 2009 May; 50(5):757-63. PubMed ID: 19330658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
    Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
    Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Lin N; Ku W; Song Y; Zhu J; Lu Z
    Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
    Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
    Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.
    Montgomery ND; Randall C; Painschab M; Seguin R; Kaimila B; Kasonkanji E; Zuze T; Krysiak R; Sanders MK; Elliott A; Miller MB; Kampani C; Chimzimu F; Mulenga M; Damania B; Tomoka T; Fedoriw Y; Dittmer DP; Gopal S
    Cancer Med; 2020 Jan; 9(2):552-561. PubMed ID: 31782984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
    [No Abstract]   [Full Text] [Related]  

  • 16. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
    He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
    Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
    Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
    Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NK-cell lymphoma using eber in situ hybridization.
    Karaarslan S; Hekimgil M; Soydan S; Ertan Y; Doğanavşargil B
    Pol J Pathol; 2015 Jun; 66(2):161-9. PubMed ID: 26247530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.